(Q43196885)

English

[177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney

scientific article published in June 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

[177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Eva Forssell-Aronsson

5

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

9

object named as

Lars Kölby

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

author name string

Christina Swärd

1

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Peter Bernhardt

2

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Håkan Ahlman

3

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Bo Wängberg

4

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Maria Larsson

6

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Johanna Svensson

7

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Rauni Rossi-Norrlund

8

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

publication date

1 June 2010

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

World Journal of Surgery

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

1368-1372

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

https://scigraph.springernature.com/pub.10.1007/s00268-009-0387-6

0 references

Interferon in the management of neuroendocrine GEP-tumors: a review

1 reference

https://api.crossref.org/works/10.1007%2FS00268-009-0387-6

21 January 2018

A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake

1 reference

https://api.crossref.org/works/10.1007%2FS00268-009-0387-6

21 January 2018

Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00268-009-0387-6

21 January 2018

Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biodistribution data from 100 patients i.v. injected with 111In-DTPA-D-Phe1-octreotide

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The use of chemotherapy in the management of neuroendocrine tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy in the treatment of neuroendocrine malignant tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chromogranin A in uremia: progressive retention of immunoreactive fragments

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diagnosis and treatment of carcinoid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chromogranin A as a determinant of midgut carcinoid tumour volume

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00268-009-0387-6

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43196885&oldid=1983611291"